

Stockholm 2007-11-16

PRESS RELEASE

Recopharma develops vaccine adjuvant

Recopharma, an innovator in adjuvant technologies for the enhancement of existing pharmaceuticals, is now entering a new phase of development. On-going animal testing is projected to be completed during the first quarter of 2008 and the company will soon be seeking international capitalization to fulfill research and development plans.

Recopharma's technology for pharmaceutical development can be utilized either for the creation of new substances or to enhance the effect of existing substances, often by means of carbohydrate-based adjuvants. This technology builds upon innovations involving recombinant glycoproteins and the ability of these mucin-like proteins to effectively retard specific biological processes.

"These breakthroughs are happening in a very promising area. Many are convinced – including the National Institute of Health (NIH) in the US – that carbohydrates represent the future of pharmaceutical drug discovery," says Stan Mikulowski, Recopharma's CEO and Senior Venture Manager of the parent company, LinkMed AB.

Presently, Recopharma is carrying out vaccine adjuvant studies at its new premises in Huddinge, Sweden in the heart of Stockholm's biotech cluster. The results of in-vivo studies evaluating these substances are expected to be available in the first quarter of 2008. The company is also planning for follow-on investment in a production facility in Luleå, which will enable industrial scale development in accordance with GMP standards (Good Manufacturing Practice).

"Our objective is to attract additional capital in the coming year. We will primarily be appealing to investors outside of Sweden because we believe that our future industrial partners will be found internationally, and in the US in particular," says Stan Mikulowski.

For further information, please contact:
Stan Mikulowski, CEO, Recopharma
Tel: +46 8 508 939 42

LinkMed owns 49.5 percent of Recopharma. LinkMed works with innovators to create and develop new life-science enterprises by providing expertise and capital. LinkMed's portfolio comprises 12 companies, six of these are active in pharmaceutical development and biotechnology, and six are active in medical technology. LinkMed is listed on the OMX Nordic Stock Exchange in Stockholm. The principal owners are FastPartner, Koncentra Holding AB and company founder, Ingemar Lagerlöf.

www.recopharma.com and www.linkmed.se

Recopharma AB, PO Box 7710, 103 95 Stockholm, Sweden

Visiting address: Drottninggatan 33

www.recopharma.com